Dasatinib monohydrate, 99%, a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM

Name: Dasatinib monohydrate, 99%, a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM | 863127-77-9
Brand: J&K Chemical
SKU: JK1020809_250_MG
Price: 228.3 USD
Availability: OutOfStock

Cat. No JK1020809_250_MG

Vendor: J&K Chemical

Product Information

Product Name

Dasatinib monohydrate, 99%, a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM

Brand Name

J&K

Product Number

1020809

CAS

863127-77-9

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

11540687

IUPAC Name

N-(2-chloro-6-methylphenyl)-2-6-4-(2-hydroxyethyl)piperazin-1-yl-2-methylpyrimidin-4-ylamino-1,3-thiazole-5-carboxamide;hydrate

InChI Key

XHXFZZNHDVTMLI-UHFFFAOYSA-N

SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO.O

Safety Information

Storage Condition

Freezer -20℃

References Data Source From Pubchem

Synthesis and application of small molecules approved for the treatment of lymphoma

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2023-12-05

DOI: 10.1016/j.ejmech.2023.115835

Repurposing of clinically proven bioactive compounds for targeted treatment of Alzheimer’s disease using molecular docking approach

Publication Name: In Silico Pharmacology

Publication Date: 2023-10-31

DOI: 10.1007/s40203-023-00173-1

Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans

Publication Name: Leukemia

Publication Date: 2023-10-03

DOI: 10.1038/s41375-023-02045-1

Expanding the Chemical Space: New Approach to Cell-Permeable Drugs

Publication Name: ACS Medicinal Chemistry Letters

Publication Date: 2023-09-20

DOI: 10.1021/acsmedchemlett.3c00389

Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase

Publication Name: European Journal of Medicinal Chemistry

Publication Date: 2023-08-05

DOI: 10.1016/j.ejmech.2023.115460

Dasatinib monohydrate, 99%, a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM

Product Information

General Information

Safety Information

References Data Source From Pubchem

Synthesis and application of small molecules approved for the treatment of lymphoma

Repurposing of clinically proven bioactive compounds for targeted treatment of Alzheimer’s disease using molecular docking approach

Dasatinib anhydrate containing oral formulation improves variability and bioavailability in humans

Expanding the Chemical Space: New Approach to Cell-Permeable Drugs

Discovery of 2,5-diaminopyrimidine derivatives as the first series of selective monomeric degraders of B-lymphoid tyrosine kinase